For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Research and development | 11,262 | 4,375* | ||
| Acquired in-process research and development | - | 17,022* | ||
| Milestone liability change in fair value | -929 | - | ||
| General and administrative | 6,881 | 4,170* | ||
| Total operating expenses | 17,214 | 25,566 | ||
| Loss from operations | -17,214 | -25,566* | ||
| Other income, net | 586 | 309* | ||
| Sermonix pre-funded warrant change in fair value | 16,320 | 1,145* | ||
| Net loss | -32,948 | -26,402* | ||
| Unrealized (loss) gain on available-for-sale securities | -9 | -1* | ||
| Comprehensive loss attributable to common stockholders | -32,957 | -26,403 | ||
| Basic EPS | -1.73 | -6.175 | ||
| Diluted EPS | -1.73 | -6.175 | ||
| Basic Average Shares | 19,027,087 | 4,275,762 | ||
| Diluted Average Shares | 19,027,087 | 4,275,762 | ||
LeonaBio, Inc. (LONA)
LeonaBio, Inc. (LONA)